The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1460
January 19, 2015
View Complete Issue         Table of Contents 2019 
Metreleptin (Myalept) - A Leptin Analog for Generalized Lipodystrophy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Metreleptin (Myalept) - A Leptin Analog for Generalized Lipodystrophy
January 19, 2015 (Issue: 1460)
Metreleptin (Myalept – Amylin), a recombinant leptin analog produced in E. coli, has been approved by the FDA to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. It has not been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Metreleptin (Myalept) - A Leptin Analog for Generalized Lipodystrophy
Article code: 1460b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.